Roche: The US and Asia outsprint Europe in life science sector

Slow regulatory processes and an unwillingness to pay the price for new medicines are contributing factors to Europe losing its significance as the home of drug development, criticizes Roche CEO.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY DANIEL PEDERSEN

Europe risks losing the race to win the favor of pharmaceutical companies, CEO at Roche Severin Schwan tells business daily Børsen.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading